Abstracts

Front-line treatment of locally advanced pancreatic adenocarcinoma with tumour treating fields concomitant with gemcitabine and nab-paclitaxel: The phase 3 PANOVA-3 study

Background Tumour Treating Fields (TTFields) are a novel, locoregional antimitotic treatment modality approved for glioblastoma and malignant pleural mesothelioma. Conti...

06/27/2022

Effects of tumor treating fields (TTFields) on gastric cancer cells and their potential concomitant application with FOLFOX

Background Gastric cancer is one of the most common types of cancers worldwide, with the intestinal pathological variant common among elderly men, and the diffuse type c...

06/27/2022

Vitamin D-based score in gastric cancer

Background Several molecular studies have explored different biomarkers to stratify gastric patients according to their relapse risk. Most of them are difficult to trans...

06/27/2022

A multicenter observational study of liposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Retrospective part

Background Nanoliposomal irinotecan and fluorouracil with folinic acid (NAL-IRI/FU/LV) is the standard regimen after gemcitabine-based therapy for unresectable or recurr...

06/27/2022

A seven-marker DNA methylation assay for non-invasive early detection of gastric cancer

Background Gastric cancer (GC) is the fifth most common and fourth most lethal cancer worldwide, with 768,793 deaths in 2020. The patients’ prognosis and survival can be...

06/27/2022

Overexpression of mir-224-3p in extrahepatic cholangiocarcinoma associated with increased dose of I131 radiotherapy: An in vitro study

Background Cholangiocarcinoma (CCA) affects the biliary tract, constituting a heterogeneous tumor, being the second most common type of primary liver cancer, a rare tumo...

06/27/2022

miR-145-3p subexpression, life habits and comorbidities in cholangiocarcinoma carcinogenesis pathway

Background Cholangiocarcinoma (CCA) is a malignant tumor that originates from cholangiocytes, epithelial cells of the bile ducts. It can be classified, according to the ...

06/27/2022

Evaluating sex as a predictive marker for response to bevacizuamb in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database

Background Previous studies suggest a possible sex-specific response to bevacizumab in metastatic colorectal carcinoma, showing a benefit in males, while the effect in f...

06/27/2022

Efficacy of 2nd-line ramucirumab (RAM) plus FOLFIRI for RAS wild-type metastatic colorectal cancer (mCRC) by prior regimen: Subgroup analysis of the JACCRO CC-16

Background There have been few studies which prospectively evaluated the efficacy and safety of RAM plus FOLFIRI after 1st-line anti-EGFR antibody-containing therapy in ...

06/27/2022

A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy

Background Both docetaxel and paclitaxel are a class of microtubule-stabilizing anticancer agents. Partial cross-resistance between docetaxel and paclitaxel was indicate...

K. Yoshimura ;

Tomo Ando , MD;

K. Nakashima ;

H. Yoshita ;

M. Sakumura ;

M. Nomura ;

M. Muto ;

Y. Horie ;

H. Takeda ;

T. Yoshii ;

Y. Tahara ;

C. Katada ;